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INTRODUCTION 
With this issue we continue the pro-
ceedings of the 50th Annual McGuire Lec-
ture Series on Cardiology in Primary Care. In 
our Scripta Medica section we present a pa-
per by Dr. James C. M. Chan on hyper-
uricemic nephropathy. 
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Results of Aortocoronary Bypass Surgery 
for Angina Pectoris 
RICHARD R. LOWER, M.D. 
SZABOLCS SZENTPETERY, M.D. 
TIMOTHY WOLFGANG , M.D. 
V. ERIC KEMP, M.D. 
From the Division of Thoracic and Cardiac Surgery, Medical College of Virginia, Health Sciences 
Division of Virginia Commonwealth University, Richmond, Virginia 
To determine the relative risks and bene-
fits of coronary bypass surgery for angina pec-
toris, we examined the results in our first con-
secutive 360 patients operated upon between 
May 1970 and December 1975 . The age 
range was 27 to 75 years; there were 309 
males and 51 females . The patients were clas-
sified clinically as having stable angina in 11 9 
cases (33%), unstable angina in 205 cases 
(5 7%) and preinfarction angina in 36 cases 
(1 0%). Unstable angina was defined as a defi-
nite recent increase in severity or frequency of 
chest pain , angina at rest or nocturnal angina. 
Preinfarction angina was defined as a syndrome 
of prolonged angina, poorly controlled by ni-
trites, occurring at rest with typical ECG changes 
of ischemia. Such patients underwent observa-
tion in the Coronary Intensive Care Unit followed 
by emergency arteriography and surgery, usu-
ally within 24 hours. 
All patients had preoperative coronary arteri-
ography and left ventriculography. Significant 
lesions were defined as 50% or more narrowing 
of the left main coronary artery and 75% or 
greater narrowing of the other vessels . Abnor-
mal left ventricular function was defined as an 
ejection fraction of less than 40% and was con-
This paper reports the clinical results of a five-year 
study of bypass surgery patients at the Medical College of 
Virginia. 
Correspondence and reprint requests to Dr. Richard 
Lower, Box 97 , Medical College of Virginia, Richmond , VA 
23298. 
sidered severe if the ejection fraction was less 
than 25% or if a large left ventricular aneurysm 
was present. Forty-three patients (1 2%) had left 
main-vessel disease, 83 (23%) had single-ves-
sel , 11 5 (32%) double-vessel, and 119 (33%) 
triple-vessel disease. One hundred and ninety-
four patients (54%) had abnormal ventricular 
function and in 84 (23%) it was considered se-
vere. Eighty-four (23%) patients had single by-
pass surgery, 135 (38%) patients had double 
bypass, and 140 (39%) patients had three or 
more grafts. One patient died in the operating 
room before bypass could be carried out. (See 
below.) Twenty-two patients (6%) had con-
comitant left ventricular aneurysm resection and 
are included in the analysis. Patients with an-
gina pectoris were excluded from surgical ther-
apy only if the left ventricular ejection fraction 
was less than 15% in the absence of a large left 
ventricular aneurysm or if there were no suitable 
vessels for grafting . 
The operation (Fig 1) generally involved 
the use of the saphenous vein as the bypass 
conduit. When the greater saphenous vein was 
unavailable or inadequate, alternative choices 
included the internal mammary artery, lesser sa-
phenous vein , and in two instances, Gortex syn-
thetic grafts. Operation was carried out under 
hemodilution and moderate systemic hypother-
mia of 28 C to 30 C, using intentional ventricu-
lar fibrillation and intermittent aortic occlusion 
for periods not exceeding 20 minutes, or alter-
natively, cardioplegia with cold hyperkalemic 
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Fig 1-Technique usually employed for aortocoronary by-
pass, utilizing saphenous vein to revascularize the distal 
right, marginal circumflex, and left anterior descending 
branches. 
solution for longer periods of arrest. When con-
sidered appropriate, coronary artery endarter-
ectomy was carried out in addition to bypass 
grafting, most frequently involving the distal 
right coronary artery and occasionally the left 
anterior descending or circumflex branches. 
Aneurysm resection was performed in a stan-
dard fashion only when there was a full thick-
ness scar with thinning of the ventricular wall; 
TABLE 1 
Estimated survival proportions for patients undergoing coronary 
bypass surgery at MCV from 1970 through May 31, 1976 
Months after Alive at Died Withdrawn Estimated proportion 
bypass beginning of during alive during surviving to end 
surgery interval interval interval of interval (cumulative) 
0-6 360 9 27 0.974 
6-12 324 1 46 0.971 
12-18 277 1 43 0.967 
18-24 233 0 35 0.967 
24-30 198 J 47 0.950 
30-36 148 3 28 0.929 
36·42 117 1 42 0.919 
42-48 74 1 24 0.905 
48-54 49 0 21 0.905 
54-60 28 0 14 0.905* 
*Standard error of the five year survival proportion is 0 .0248. 
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Fig 2-Proportion of patients surviving following coronary 
graft surgery at the Medical College of Virginia from 1 970 
through May 31, 1976. 
frequently, an intraventricular thrombus was re-
moved during aneurysm resection_ 
Results 
There were two operative deaths and four 
postoperative deaths within the first month for a 
total operative mortality of 1. 7%. One operative 
death in a 54-year-old female with stable an-
gina and two-vessel disease resulted from an 
iatrogenic intraoperative aortic dissection, with 
death occurring before extracorporeal circula-
tion could be established. This was the only op-
erative or postoperative death in the group of 
patients with stable angina. The second oper-
ative death was in the only patient who could 
not be weaned from cardiopulmonary bypass. 
Postmortem examination of the 62-year-old 
male revealed extensive three-vessel disease, 
an old anterior wall infarction, and a posterior 
wall infarction (unsuspected preoperatively) esti-
mated to be of two to three days' duration . No 
other patient required intraoperative or post-
operative intra-aortic balloon assist. The oper-
ative mortality in the last four years of the study 
was 0. 7% . There were four early postoperative 
deaths within one month: one from acute myo-
cardial infarction occurring in a non~ 
revascularized area one week after operation, 
one from acute renal failure in a patient with 
chronic renal disease, one from an unsus-
pected, ruptured abdominal aneurysm in an 
obese patient, and one from a dissecting aneu-
rysm in a patient with severe myxedema. 
During this same period of study, 33 pa-
tients had operations for valve disease and con-
comitant coronary bypass grafting with no oper-
ative or hospital deaths in this group. However, 
these patients were not included in the analysis 
of surgery for angina pectoris and are not fur-
ther considered in this report. 
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TABLE 2 
Estimated proportionsreporting angina free status following 
coronary bypass surgery at MCV from 1970 through May 31, 1975 
Years Angina free at Symptoms Withdrawn Cumulative proportion 
after beginning of returned during angina free during angina free at end of 
graft interval interval interval interval 
0-1 264 78 0 0.706 
1-2 187 22 46 0.611 
2-3 119 6 37 0.575 
3-4 75 1 43 0.564 
4-5 54 1 20 0.552* 
*Standard error for proportion angina free five years after surgery is 0.035. 
Within the series of patients operated 
upon for angina pectoris, the perioperative in-
farction rate was studied in 1 00 consecutive pa-
tients with serial ECGs, vectorcardiography, 
and serum enzymes. A new perioperative in-
farction, one of which was fatal, was diagnosed 
in four patients. 
There were 1 3 late postoperative deaths 
(3 .4 % ) occurring two months to four years after 
operation; all were in patients who were clas-
sified preoperatively as unstable or having 
preinfarction angina. In each case there was ab-
normal ventricular function demonstrated pre-
operatively and in six patients it was considered 
severe. Two patients had aneurysmectomy in 
addition to bypass. Twelve of the 13 patients 
had documented myocardial infarction pre-
operatively. Ten of the patients had three-vessel 
disease and three of the patients two-vessel dis-
ease. Three of the deaths were non-cardiac in 
origin; one of disseminated malignancy and two 
from stroke. There have been no operative or 
postoperative deaths in patients with single-ves-
sel disease. No late deaths have occurred dur-
ing the period of this study in patients with a 
TABLE 3 
Estimated proportions reporting improvement following 
coronary bypass surgery at MCV from 1970 through May 31, 197'> 
Years Improved at Failed Withdrawn Cumulative proportion 
after beginning of during improved during improved at end 
graft interval interval interval of interval 
0-1 265 12 0 0.955 
1·2 253 2 75 0.946 
2-3 176 71 0.939 
3-4 104 60 0.939 
4.5 44 34 0.939* 
* Standard Error for proportion improved five years after surgery is 0 .016. 
preoperative classification of stable angina pec-
toris . There were no operative or early post-
operative deaths in patients with left main-ves-
sel disease, and two late postoperative deaths 
have occurred in this group. Statistical analysis 
of all patients by life table methods (Table 1 and 
Fig 2), including the operative deaths, revealed 
a five-year expected survival rate of approxi-
mately 91 %. 
To evaluate the degree of palliation and its 
duration , follow-up evaluation was carried out in 
all surviving patients who had survived more 
than one year after operation at the time of the 
study. Evaluation consisted of personal exami-
nation, mail questionnaire, or telephone inter-
view, with 1 00% follow-up. On the basis of the 
interviews, patients were classified as 1) asymp-
tomatic, 2) impro\;'ed, though with some angina, 
or 3) unimproved. An attempt was made to de-
fine when in the postoperative course angina 
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Fig 3-Proportion of patients reporting improved status and 
proportion reporting angina-free status following coronary 
vein graft surgery from 1970 through May 31, 1976 at the 
Medical College of Virginia . 
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had reappeared or when therapeutic failure had 
occurred. Similar life table analysis of the dura-
tion of palliation (Tables 2 and 3, Fig 3) re-
vealed that at five years 55% of the patients 
were anticipated to be pain-free and 93% 
asymptomatic or improved, with 7% either un-
improved or worse. 
Conclusions 
These results appear to show that aorto-
coronary bypass grafting for angina pectoris 
can be carried out with relative safety and effec-
tiveness in the majority of properly selected pa-
tients . The risk appears particularly low in pa-
tients with single-vessel disease, those with 
stable angina, and those with good left ventricu-
lar function . The operative risk also appears ap-
propriately low for all patients with left ventricu-
lar ejection fraction above 1 5% so long as 
suitable graftable vessels are present even if 
concomitant ventricular aneurysm resection is 
required. Determination of the ultimate value of 
aortocoronary bypass grafting in terms of pro-
longation of life and duration of palliation will re-
quire several more years of analysis in view of 
the generally progressive nature of the disease 
both in the native circulation and in the bypass 
grafts. However, the analysis of this group of 
patients from one to five years after operation 
strongly suggests that operation has provided 
improved longevity as well as effective pallia-
tion . 
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Surgical Treatment of Mitral Valve Disease 
ZUBAIR UL HASSAN, M.D. 
Assistant Professor of Medicine, and Director, Cardiac Catheterization Laboratory, McGuire Veterans 
Administration Hospital, Richmond, Virginia 
This paper discusses the indications for 
surgery in mitral valve disease by comparing the 
natural history of the disease, as it can best be 
determined from the literature, with the results 
of various surgical procedures. It may be stated 
at the outset, however, that there are no con-
trolled studies comparing medical and surgical 
treatment nor are they likely to be carried out in 
the near future. 
Mitral Stenosis 
1. Detection. While the auscultatory find-
ings of mitral stenosis are characteristic , many 
patients go undetected by routine clinical exam-
ination; it is, therefore, important to be aware of 
the special syndromes with which they may 
present (Table 1 ). 
Mitra! stenosis is much more common in 
women and should be looked for particularly in 
those who are young or middle-aged . The con-
dition is predominantly a sequel to rheumatic 
heart disease which is prevalent among large 
families from lower socioeconomic groups. The 
availability of M-mode echocardiography in re-
cent years has been of great help in the detec-
tion of mitral stenosis, since this procedure has 
nearly 1 00% sensitivity and the specificity is al-
most as good . With the two-dimensional echo-
cardiogram the degree of stenosis can be mea-
sured with great precision by mapping out the 
valve area. Echocardiography has thus elimi-
nated the need for cardiac catheterization either 
for the detection or quantification of mitral ste-
nosis, and cardiac catheterization is now em-
Correspondence and reprint requests to Dr. Zubair ul 
Hassan, McGuire VA Hospital , 1201 Broad Rock Road , 
Richmond, VA 23249. 
ployed only preoperatively for the detection and 
assessment of associated lesions. 
2. Natural history. Bland and .Jones in 
their classical 20-year study of 1 ,000 patients 
with acute rheumatic fever showed the extreme 
variability in the rate of progression of mitral ste-
nosis in different patients. 1 Some patients devel-
oped mitral stenosis within 5 years after the first 
attack of rheumatic fever while others were rela-
tively well even 50 years later; however, a com-
posite average can be deduced from this and 
other studies. In the preantibiotic era, mitral ste-
nosis was clinically detectable approximately 
1 0 years after the onset of acute rheumatic fe-
ver, symptoms were minimal in the next 10 
years unless pregnancy or complications oc-
curred (for example, endocarditis or atrial fibril-
lation}, and in the next 20 years symptoms in-
creased progressively with development of 
pulmonary hypertension , heart failure , and sys-
temic embolism, leading to death , approxi-
mately 40 years after the onset of rheumatic fe-
ver, at an average age of 48 (Fig 1 ). 1- 3 
It is my impression that mitral stenosis 
today shows a slower rate of progression in the 
industrialized countries, mainly because the use 
of antibiotics has considerably improved the 
rate of recurrence of rheumatic fever and the 
treatment of endocarditis. 
One of the most useful studies of the natu-
ral history of mitral stenosis is by Olesen and 
Baden who classified their patients according to 
the New York Heart Association (NYHA) classifi-
cation and compared the non-surgical groups 
seen during the years 1933-1 950 with the ini-
tial 1 65 consecutive patients operated on dur-
ing the years 1950-1955 (Fig 2).4 Most studies 
of surgical treatment of mitral stenosis have 
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TABLE 1 
Some Presenting Syndromes in Mitral Stenosis 
EXERTIONAL DYSPNEA OR PULMONARY 
EDEMA WITHOUT GENERALIZED CARDIOMEGALY 
A TRIAL FIBRILLATION 
SYSTEMIC EMBOLISM 
(STROKE, MYOCARDIAL INFARCTION, HEMATURIA, 
ETC.) 
HEMOPTYSIS WITHOUT PULMONARY INFECTION 
RESTRICTIVE AND OBSTRUCTIVE LUNG DISEASE 
WITHOUT SMOKING HISTORY 
used Olesen and Baden's non-surgical patients 
for comparison . In NYHA Class II patients with 
normal sinus rhythm the ten-year survival was 
80%. At the other extreme over 50% of Class 
IV patients were dead within five years and all 
were dead within eight years. 
Asymptomatic 
Mild 
Moderate 
Severe 
Total 
Disability 
Death 
Atrial '.J 
fibrulotr 
Bacterial 1 
endocarditis 
I 
3. Choice of operations and results . The 
possibility of correcting the mechanical problem 
of mitral stenosis surgically was first discussed 
around the turn of the 20th century. The first at-
tempts at surgical correction were made in the 
1 920s, but mitral valvotomy has come to be 
recognized as a generally acceptable method of 
treatment only since 1948. Today several dif-
ferent surgical procedures are available for the 
repair of mitral valve disease, some of the more 
common being listed in Table 2. 
The operative and postoperative morbidity 
and mortality rates are very low for mitral com-
missurotomy but considerable when mitral valve 
replacement with a prosthesis is necessary. It 
is important, therefore, to determine pre-
operatively whether the patient with mitral ste-
nosis will require commissurotomy or valve re-
placement. Table 3 gives some of the signs that 
determine this decision. Successful mitral com-
10 20 30 40 
YEARS AFTER ACUTE ATTACK 
4-6 cm2 1.5 -2.5 cm2 1.1-1.5 cm2 0.6-1.0 cm2 
Rest LA N LA 
... LA u PA N PA ... PA Uoruo 
co N co N co t orftt 
Exer LA 
... LA u 
PA ... PA u 
co 
... co ... 
Fig 1-Natural progression of mitral stenosis. Clinical course, pathology and hemodynamic changes are correlated. Valve area 
is indicated below each diagram of valve. CO = cardiac output; Exer = exercise; LA = left atrial pressure; N = normal; PA = 
pulmonary arterial pressure; i = decreased; j = increased. 
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Fig 2---Mitral Stenosis: Survival curves of surgery and medically treated patients. A. Normal sinus rhythm (NSR), NYHA Class II, 
B. NSR, NYHA Class Ill; C. Atrial fibrillation and NYHA Class II or Ill; D. NYHA Class IV. Vertical bars give 2 standard errors 
above and below each point. 
missurotomy is not possible if significant regur-
gitation accompanies stenosis or if the valve is 
heavily scarred, markedly deformed, or calci-
fied and immobile. Attempts at valvotomy in cal-
cified valves result in fracture of the valve with 
resultant insufficiency rather than cleavage of 
the commissures. Lack of valve mobility is evi-
dent clinically by the absence of an opening 
snap and the presence of a muffled first heart 
sound; calcification can be detected by fluoros-
copy and echocardiography. Repeated com-
missurotomies also cause extensive scarring 
and deformity which necessitate valve replace-
ment. 
Olesen and Baden showed that 'closed' 
TABLE 2 
Common Operations Available for Mitral Valve 
Disease 
• COMMISSUROTOMY 
CLOSED 
OPEN 
• VALVE REPAIR 
ANNULOPLASTY 
VAL VULOPLASTY 
CARPENTIER RING 
• VALVE REPLACEMENT 
CAGE AND BALL VAL VE 
TILTING DISC VAL VE 
PORCINE TISSUE VAL VE 
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TABLE 3 
Signs Indicating Probable Need for Valve 
Replacement in Mitral Stenosis 
• INTENSITY OF S1 OR OPENING SNAP REDUCED 
• SIGNIFICANT MITRAL INSUFFICIENCY 
• DENSE CALCIFICATION OF MITRAL VALVE 
• PRIOR MITRAL SURGERY 
mitral commissurotomy (that is, commis-
surotomy without cardiopulmonary bypass or 
'open'-heart surgery) improved survival in all but 
minimally symptomatic patients in normal sinus 
rhythm . 4 Long-term survival was adversely af-
fected by the presence of preoperative pulmo-
nary hypertension or postoperative mitral in-
sufficiency. Ellis, Harken and Black reported 
essentially similar results in a much larger series 
of 1 ,000 surgical cases. 5 
In the United States, most institutions use 
open mitral commissurotomy (that is, with car-
diopulmonary bypass) as the procedure of 
choice for mitral stenosis. The results of open 
commissurotomy are probably superior to the 
closed operation , although it is a more ex-
pensive procedure. Improvements in surgical 
technique have markedly reduced the incidence 
of systemic embolization and mitral in-
sufficiency, which were the principal dangers of 
mitral commissurotomy in earlier days. The 
mortality from mitral commissurotomy today is 
less than 1 % when the operation is done at an 
optimal time and most survivors experience im-
provement in their symptoms. 6 
When mitral stenosis can be treated with 
commissurotomy, the operation should be rec-
ommended as soon as symptoms interfere with 
the normal enjoyment of life or at the earliest 
signs of complications. In a substantial minority 
of patients, the valve restenoses after several 
years with recurrence of symptoms. Additional 
surgery should be considered in these patients. 
The other types of mitral valve surgery will 
be discussed with the treatment of mitral in-
sufficiency. 
Mitral Regurgitation 
The causes of mitral regurgitation are nu-
merous; however, it is usually caused by con-
genital heart defects in young children, rheu-
matic heart disease or mitral valve prolapse in 
young adults, and coronary artery disease in 
older patients. The systolic apical murmur radi-
ating into the axilla is usually easy to detect and 
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is almost diagnostic of mitral regurgitation, al-
though occasional patients with aortic stenosis 
have their murmur referred to the mitral area. 
Rupture of chordae tendineae to the posterior 
mitral leaflet may produce a murmur loudest at 
the sternum, simulating aortic stenosis. After 
mitral valve replacement, significant mitral re-
gurgitation may occur silently but should be sus-
pected if left ventricular failure or hemolytic 
anemia develops unexpectedly. 
Detailed studies of the natural history of 
mitral regurgitation according to severity of the 
lesion or staging by symptoms are not available. 
Some impressions can be drawn from the pro-
spective study of rheumatic fever by Bland and 
Jones.1 The prognosis of asymptomatic, mild, 
chronic mitral regurgitation without cardiome-
galy is no different from that of the normal popu-
lation ; however, when significant symptoms are 
present with moderate-to-marked cardiome-
galy, life expectancy is considerably shortened . 
In Rapaport's experience approximately 20% of 
the patients with mitral regurgitation were dead 
within five years and 40% within ten years after 
their initial diagnosis. 3 
Another consideration in mitral regurgita-
tion regarding prognosis is the cause of the le-
sion. Most patients with mitral valve prolapse 
(click-murmur, Barlow syndrome) have a 
nonprogressive lesion . Mitra! regurgitation sec-
ondary to chronic left ventricular failure and di-
latation (for example, cardiomyopathy, hyper-
tension) usually does not respond well to surgi-
cal treatment. In contrast with chronic mitral in-
sufficiency, acute mitral insufficiency is very 
poorly tolerated and leads to rapid heart failure. 
Acute mitral regurgitation usually results from 
rupture of papillary muscles, chordae tendineae 
or valve leaflets due to infarction, infection or 
trauma, and occasionally spontaneously. In 
acute cases more attention should be paid to 
the severity of the hemodynamic lesion, as de-
termined by physical signs and cardiac cathe-
terization, than to the symptoms. 
The combined lesion of mitral stenosis 
and regurgitation is usually due to rheumatic 
heart disease and is treated like mitral regurgita-
tion because most patients require mitral valve 
replacement. 
Mitral Valve Repair 
The concept of repairing the valve instead 
of replacing it with a prosthesis is extremely at-
tractive, particularly for younger patients. 7 - 9 It 
avoids the problems of thromboembolism, in-
fection and hemolysis consequent upon the in-
troduction of a foreign body into the blood-
stream. The proponents of valve repair claim 
that it is feasible in a majority of patients with mi-
tral regurgitation, but others have largely 
avoided it. Several different techniques have 
been described. Annuloplasty reduces the size 
of the valve orifice by plication of the annulus 
fusing the peripheral portions of the mitral com-
missures. Complete obliteration of mitral in-
sufficiency is frequently not possible by this 
technique and postoperative dilatation of the 
mitral annulus may necessitate valve replace-
ment at a later date. Valvuloplasty is a spec-
tacularly successful and curative operation for 
many cases of ruptured chordae tendineae. The 
redundant untethered portion of the posterior 
leaflet is obliterated by pleating with sutures. 
The Carpentier ring is a slightly irregular biar-
cuate stainless steel ring wrapped in a teflon 
collar for sewing which has been recently in-
troduced as an aid to valvuloplasty. The ring 
prevents further dilation of the valve, and the 
sewing collar is used to anchor the sutures and 
A B 
remold the deformed valves to approximate nor-
mal anatomy. Risk of thromboembolism and 
endocarditis is not significantly increased with 
the use of the Carpentier ring . At present, valve 
repair should be strongly considered in younger 
patients and in those with mitral insufficiency 
secondary to rupture of the posterior leaflet 
chordae tendineae. With continuing improve-
ments in technique, valve repair is likely to be-
come possible in a larger proportion of patients. 
The risk of valve repair is minimal, and marked 
symptomatic improvement occurs after suc-
cessful surgery, but it is not possible to decide 
preoperatively whether repair or valve replace-
ment will be necessary in a specific patient. The 
indications for valve repair are therefore the 
same as for valve replacement as discussed be-
low. 
Mitral Valve Prostheses 
Three main types of prostheses are cur-
rently in use (Fig 3). Various models of the Starr-
Edward heart valves are examples of the cage-
ball type of prosthesis. Blood flows turbulently 
around the occluding ball in contrast to the lami-
nated flow in the normal valve. Long experience 
c 
Fig 3-Three commonly used mitral valve prostheses. A. Starr-Edward Model 6120; B. Bjork-Shiley; C. SGP Hancock Porcine 
Model 342. 
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with these valves has shown them to be durable 
and reliable. The main problem is thromboem-
bolism which is reduced but not eliminated by 
anticoagulants. Traumatic hemolysis may occur 
in models of the valve with cloth-covered struts. 
Another problem is the very loud closing click 
with some models. This sound can occasionally 
be heard by the unaided ear across the room 
from the patient. The incidence of infection of 
the prosthesis is probably similar to the other 
prosthetic valves. 
Tilting disc valves, such as the Bjork-
Shiley, have a more physiological blood flow 
and a low profile so that the valve does not oc-
clude the left ventricular cavity. The major ad-
vantage of this valve is that the sewing ring is 
not disproportionately larger than the internal lu-
men and these valves are therefore associated 
with the lowest transvalvar gradients among all 
prosthetic heart valves . However, anti-
coagulation is needed and the closing click can 
be quite noisy. This is the prosthetic valve of 
choice in patients with a small mitral valve an-
nulus. 
Glutaraldehyde-treated porcine hetero-
grafts are becoming increasingly popular be-
cause of low thrombogenicity even without anti-
coagulation. These valves consist of porcine 
aortic valve tissue mounted on a man-made 
frame. Flow is central, very much as in the nor-
mal valve, but the sewing ring is considerably 
larger than the internal lumen, and large trans-
valvar gradients may be present post-
operatively, particularly with the smaller-sized 
sewing rings. Long-term durability is another 
major concern . Nevertheless, this is the pros-
thesis of choice when anticoagulation is con-
traindicated. 
Characteristics of the three valves dis-
cussed above are compared in Table 4. 
Results of valve replacement. Compara-
tive studies of different types of valve pros-
theses are not available at present. It appears, 
however, that the operative mortality for the dif-
ferent types of prostheses mentioned above is 
roughly comparable, and the risk factors for op-
erative mortality and long-term results are also 
similar. The most important risk factors for early 
operative mortality are advanced heart failure 
and marked cardiomegaly, particularly left atrial 
enlargement (Fig 4 ). 6 · 10 The long-term results 
are adversely affec!ed in patients with marked 
left atrial enlargement or pulmonary hyper-
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TABLE 4 
Comparison of Three Most Commonly Used Prosthetic 
Heart Valves. Pros and Cons Graded from One to 
Three Plus. S-E = Starr-Edward; B-S = Bjork-Shiley; 
P-H = Porcine Hancock. 
S-E B-S P-H 
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ct! NOISE +++ ++ -(/) 
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tension. Most survivors of the operation show 
symptomatic improvement, but their survival 
curve does not parallel that of the general popu-
lation (Fig 5). Young patients with severe mitral 
regurgitation show a remarkable reduction in 
cardiac size following successful surgery, 
whether valve repair or valve replacement. Mi-
tral valve replacement is recommended in all 
patients with significant symptoms, that is, 
NYHA Class Ill or IV. It is also indicated in acute 
severe mitral regurgitation and significant mitral 
regurgitation with progressive cardiomegaly or 
pulmonary hypertension, even when symptoms 
are less impressive (Table 5). It is advisable not 
to wait until advanced stages of heart failure, 
cardiac enlargement, or pulmonary vascular 
changes occur, but unfortunately patients are 
all too frequently in this condition when they first 
seek, or are referred for, valve surgery. 
In summary, the natural history of mitral 
valve disease is discussed and compared with 
various surgical procedures. Life expectancy is 
considerably shortened when mitral stenosis is 
accompanied by significant symptoms or com-
plications. Mitral commissurotomy is a relatively 
benign procedure (< 1 % mortality) which im-
proves survival and symptoms in these patients. 
Chronic mild mitral regurgitation is tolerated 
well, but progressive cardiac dysfunction occurs 
when regurgitation is severe, particularly if it de-
velops acutely. Valve repair can be performed 
in some cases with a low mortality and very low 
postoperative morbidity. Most patients with in-
competent valves require valve replacement in 
which the average surgical mortality is approxi-
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EARLY OPERATIVE MORTALITY 
ISOLATED MITRAL VALVE REPLACEMENT 
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Fig 4-Early operative mortality in isolated mitral valve replacement with Model 6120 Starr-Edward prosthesis, Mayo Clinic 3-
66 to 1 -7 2; A = mortality according to preoperative NYHA classification ; B = mortality according to preoperative left atrial (LA) 
size. 
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Fig 5--Late survival and systemic thromboembolism in surgical survivors of isolated Starr-Edwards mitral valve replacement 
with model 6120 prosthesis compared to normal life expectancy. 
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TABLE 5 
Indications for Valve Replacement in Mitral 
Regurgitation 
NYHA CLASS Ill OR IV 
SIGNIFICANT ENLARGEMENT OF LEFT ATRIUM OR 
VENTRICLE 
PULMONARY HYPERTENSION 
ACUTE SEVERE MITRAL REGURGITATION 
mately 5%; thromboembolism is the most seri-
ous postoperative problem . 
Surgical mortality is markedly increased in 
advanced heart disease (NYHA Class IV) and 
surgical treatment should therefore be consid-
ered in all patients with mitral valve disease be-
fore this stage is reached. 
Figure 1 is taken in part from Proceedings of the Royal 
Society of Medicine (60: 1 009-1 01 5, 1 96 7) and the 
American Journal of Cardiology (35:221-227, 1975) by 
permission. 
Figure 2 is adapted from the Scandinavian Journal of 
Thoracic and Cardiovascular Surgery (3:119-124, 1969) 
by permission. 
Figure 4 adapts data found in Barnhorst et al , Ameri-
can Journal of Cardiology (35 :228-233 , 1975). 
Figure 5 is adapted from the American Journal of Car-
diology (35 :228-233, 1975) by permission . 
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Assessment for Surgery for Aortic Valve 
Replacement 
JOHN QUINN, M.D. 
Assistant Professor of Medicine and Cardiology, Department of Medicine, Medical College of Virginia , 
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
Surgical management of symptomatic 
aortic valve disease has been successful in im-
proving both survival and function. Data re-
ported from the literature suggest an operative 
mortality of from 5% to 8%, with a lower risk for 
elective replacement, and a 65% to 75% 1- 3 
five-year survival rate as opposed to 50% to 
60%4 in non-surgical patients with symptomatic 
aortic valve disease. 
Aortic Stenosis 
Valve replacement for aortic stenosis is 
usually indicated when angina pectoris, ex-
ertional syncope or congestive heart failure oc-
cur. Previous statistics suggest that with angina, 
which is the most common symptom, 50% of 
patients are dead within five years and with con-
gestive heart failure, 50% are dead within two 
years, 5 usually as a result of sudden death. In 
the adult, coronary disease is present in approx-
imately half the cases of aortic stenosis. The 
etiology of angina may thus be multifactoral 
which makes this the most difficult of the major 
symptoms to assess. Obviously the severity of 
coronary disease influences subsequent sur-
vival; coronary bypass surgery at the time of 
valve replacement does not substantially alter 
perioperative mortality. At the present time a 
congenitally malformed bicuspid valve is the 
most common cause of aortic stenosis in the 
adult. f-meumatic aortic stenosis is now less 
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common and occasionally calcific tricuspid ste-
nosis (''aortic stenosis of the elderly'') is seen . 
Accurate clinical assessment of the sever-
ity of aortic stenosis may be difficult, especially 
in the elderly and in the patient with congestive 
heart failure. As cardiac output falls, the flow 
over the aortic valve diminishes and therefore 
the intensity of the murmur decreases. The 
usual physical findings with severe aortic ste-
nosis include a narrow pulse pressure primarily 
because of decreased systolic blood pressure; 
a diminished carotid pulse volume with a slow 
rise to peak upstroke; a thrill often palpable in 
the second right interspace; and a murmur, 
most intense in the aortic area, typically of a 
crescendo-decrescendo type which peaks late 
in systole. An S4 gallop rhythm secondary to 
decreased ventricular compliance is audible. In 
the adult, the presence of an ejection click usu-
ally occurs only with pliable valves; the second 
sound may be diminished and becomes single 
as left ventricular ejection time increases. The 
electrocardiogram usually shows left ventricular 
hypertrophy. In the absence of congestive heart 
failure or concomitant multivalve disease, the 
chest X-ray reveals a normal heart size. The as-
cending aorta may be dilated secondary to 
post-stenotic dilatation, but the aortic knob is 
usually small as opposed to patients with gener-
alized tortuosity of the aorta. Ordinarily the adult 
has valvular calcification which is seen better by 
fluoroscopy. The greater the calcification, the 
more likely the stenosis will be severe; thus fluo-
roscopy may provide useful information in se-
lecting patients for catheterization . Single di-
mensional echocardiography reveals dense 
MCV QUARTERLY 15(2):55-57, 1979 I 55 
echoes in the aortic root but does not yield in-
formation on the severity of the valvular ste-
nosis. The newer two-dimensional studies fre-
quently allow one to determine a cross-sectional 
area, and show promise in the future of effec-
tively selecting patients for catheterization by a 
non-invasive method when the clinical findings 
do not suggest severe stenosis. 
Catheterization is the single best method 
to assess severity. With normal cardiac output, 
a large systolic gradient of greater than 50 to 
70 mm Hg is usually seen with symptomatic 
stenosis. As cardiac output falls for a given 
fixed-valve area, the gradient falls; thus the 
valve area calculation is of major importance 
when the output is diminished. The usual aortic 
valve area is approximately 3 cm 2 ; the calcu-
lated valve area determined by hydraulic for-
mula, using the observed gradient and mea-
sured cardiac output, should be less than 1 cm 2 
with symptomatic aortic stenosis and is less 
than 0 . 7 cm 2 with severe aortic stenosis. 
The decision regarding replacement in the 
asymptomatic patient is not clear. Studies in 
children ages 2 to 21 6 with gradients greater 
than 80 mm Hg reveal that over a period of time 
the group operated upon was functionally better 
than the medical group; however, survival data 
were similar. These findings may not be similar 
in the adult; however, if the gradient is severe or 
if progressive electrocardiogram or chest x-ray 
changes occur then one might consider sur-
gery. 
Aortic Regurgitation 
Chronic aortic regurgitation has a more 
varied etiology and, to a large extent, progres-
sion of disease is dependent on the cause. In 
general the murmur is detected years before 
symptoms occur, and because progression, 
even with a large regurgitant volume, is often 
slow, the decision regarding valvular replace-
ment is often more difficult than with aortic ste-
nosis. Years may pass before development of 
fatigability and then several years more until 
frank congestive heart failure occurs, resulting 
in an average survival of approximately two 
years after the onset of heart failure. 
Acute severe aortic regurgitation second-
ary to endocarditis, aortic dissection or trauma 
usually leads to immediate surgery; thus the de-
cision as to valve replacement is not as difficult 
as with chronic aortic regurgitation . 
In brief, several features on clinical exami-
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nation that suggest substantial regurgitation are 
widened pulse pressure with a low diastolic 
valve, bisferins carotid pulsation, rapidly col-
lapsing peripheral pulses, and a displaced 
apical impulse. The absence of a diastolic pres-
sure of less than 70 mm or a widened pulse 
pressure with the pulse pressure greater than 
50% of the peak systolic in patients without 
congestive heart failure usually excludes severe 
aortic regurgitation . The rapidly collapsing pul-
ses seen with chronic aortic regurgitation are 
also seen in high-output states and are not spe-
cific. The typical murmur is a decrescendo dias-
tolic type which lengthens as the regurgitant 
fraction increases, that is, the longer the mur-
mur, the more severe the regurgitation. The 
other auscultatory sign of significant aortic re-
gurgitation is the presence of an Austin Flint 
murmur, that is, a middiastolic apical rumble 
which may be produced by turbulence because 
of closure of the mitral valve in diastole by the 
aortic regurgitant jet, with antegrade flow 
through the mitral valve, as 75% of the stroke 
volume may return to the left ventricle . A sys-
tolic flow murmur is often heard but is not help-
ful in assessing severity. An S3 gallop rhythm is 
common. 
The electrocardiogram in severe aortic re-
gurgitation should show left ventricular hyper-
trophy. The chest x-ray reveals a dilated left 
ventricle. 
The echocardiogram usually shows a di-
lated left ventricle with shuddering of the ante-
rior mitral leaflet because of the regorgitant jet 
but is generally not helpful in assessing severity. 
If the mitral valve closes prematurely because of 
very high left ventricular end diastolic pressure 
then this is a sign of severe aortic regurgitation; 
however, clinically there is little difficulty in es-
tablishing severity at that point. One study sug-
gests that if the end systolic dimension is 
greater than 5.5 cm 1 then the incidence of sub-
sequent complications is high and surgery may 
be indicated. These data have not yet been fully 
substantiated, and concomitant coronary dis-
ease or a myopathic process limits the value of 
this one finding . 
Cardiac catheterization will yield informa-
tion regarding hemodynamics and the degree 
of regurgitation. 
The symptomatic patient is usually helped 
by valve replacement, but the decision to oper-
ate in an asymptomatic, or minimally sympto-
matic , patient with clinically severe regurgitation 
is a difficult one. Ideally one would want a bat-
tery of noninvasive predictors such as an elec-
trocardiogram, a chest x-ray, and an echo-
cardiogram to predict the subsequent course 
and therefore to select the ideal time for sur-
gery. Hirshfeld8 could establish no relationship 
between postoperative improvement or survival 
and preoperative heart size by x-ray, ECG, or 
New York Heart Association functional class. 
Spagnuolo9 found that in young persons with 
rheumatic aortic regurgitation 65% developed 
angina, heart failure, or died within three years if 
they had the combination of 1) diastolic pres-
sure of less than 40 , 2) cardiomegaly, and 3) 
left ventricular hypertrophy on electrocar-
diogram. With this triad of findings aortic valve 
replacement has been suggested. 
Another consideration as to valve replace-
ment for aortic regurgitation is that of preserva-
tion of myocardial function as in severe pro-
1 on g ed aortic regurgitation ; irreversible 
myocardial changes may occur which cannot 
be corrected by surgery. The regurgitant vol-
ume will be eliminated by surgery and thus the 
patient may have symptomatic improvement, 
but myocardial function will remain poor; in ad-
dition the long-term survival rate with depressed 
left ventricular function is worse. 8 In the future 
one would hope to replace valves at the point 
just prior to irreversible myocardial changes, but 
at present no tests are available to assess early 
irreversible changes accurately. Currently, exer-
cise nuclear gated scans are being evaluated 
for exercise-induced wall motion abnormalities 
which may indicate early irreversible changes 10 ; 
the future of aortic regurgitation evaluation lies 
in assessing left ventricular function for timely 
valve replacement. 
In summary , valve replacement is in-
dicated for both symptomatic aortic stenosis 
and insufficiency. The prognostically important 
symptoms associated with aortic stenosis are 
angina, syncope or presyncope, or presyncope 
and congestive heart failure. The asymptomatic 
patient with aortic stenosis may be considered 
for valve replacement , but the long-term advan-
tages of surgery in this group are not clear for 
adults. The symptomatic patient with severe 
aortic regurgitation is also a surgical candidate. 
The asymptomatic patient with clinically severe 
aortic insufficiency who has, or subsequently 
develops, left ventricular hypertrophy on elec-
trocardiogram, with cardiomegaly and low dias-
tolic blood pressure, may also be considered for 
valve replacement; however, the indications are 
not as clear-cut as with the symptomatic pa-
tient. In the future more emphasis may be 
placed on left ventricular function to determine 
early irreversible changes so that ventricular 
function may be preserved postoperatively. Ar-
guments favoring earlier valve replacement are 
decreasing perioperative mortality, modification 
in prosthesis design to reduce long term compli-
cations, and higher perioperative mortality in the 
severely ill patients. The major argument 
against earlier valve replacement is that there is 
not yet an ideal valve; thus the potential for such 
complications as endocarditis, thromboembo-
lism, and valve malfunction still exists. 
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Recent Techniques in Echocardiography: 
Two-Dimensional Echocardiography 
KIRAN B. SAGAR, M.D. 
Assistant Professor of Medicine, Division of Cardiology, and Director of Echocardiography, Medical 
College of Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
Conventional M-mode echocardiography 
is a widely used noninvasive diagnostic tech-
nique. It allows bedside assessment of cardiac 
chamber dimensions, valve motion and left ven-
tricular function . The limitations of this tech-
nique are that it (1) provides only a one-dimen-
sional (icepick) view of the heart, (2) displays 
cardiac structures in an unfamiliar form that 
bears no resemblance to cardiac anatomy, and 
(3) does not provide information regarding spa-
tial orientation of cardiac structures. 
These limitations led to the development 
of two-dimensional (2-D) real-time echo-
cardiography in the last decade. ,_4 The 2-D 
echo allows simultaneous visualization of car-
diac structures in real time through multiple 
planes. 
There are two types of commonly used 2-
D echocardiography: 
1 . Mechanical sector scanner. A single 
crystal transducer is mounted on a motor 
and oscillates in an arc of 30° .2 It is less 
expensive than the phased array scanner 
and can be interphased with the existent 
M-mode echocardiograph. The disadvan-
tages are noisiness, vibrations which the 
patient feels on the chest, and a narrow 
angle image. Newer, wide-angle mechan-
ical sector scanners will overcome the las' 
problem. 
2. Phased array wide-angle sector scan-
ner. This technique requires multiple ele-
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ments in the transducer and there is a se-
ries of delays in the firing of the individual 
elements so that the ultrasonic wave front 
is at an angle to the transducer. By con-
trolling the time sequence, the beam is 
electronically swept through a wide-angle 
sector. 4 
The patient is examined lying supine or in 
the left lateral position with head slightly ele-
vated. The echo information is recorded on a 
video cassette which can be stored and re-
played later. The figures shown here are still 
frames of the cine. 
The cardiac imaging is done in the follow-
ing multiple views: 
1 . Parasternal long axis. The ultrasonic beam 
is parallel to the long axis of the left ventricle. 
Figure 1 is the anatomic section of the heart ob-
tained in a presumed long axis plane of the left 
ventricle. Figure 2 shows the same structures 
seen with the 2-D echo. This view allows evalu-
ation of pathology of the .aortic root, aortic 
valve, mitral valve, and left ventricle. 
2 . Parasternal short axis. This view is obtained 
by rotating the transducer through 90 ° and pro-
vides tomographic sections of the heart from 
the apex of the left ventricle to the aortic root. 
Figures 3 and 4 show the anatomical and 2-D 
echo sections at the level of the papillary mus-
cles; Figure 5 shows the 2-D echo sections at 
the level of the mitral valve. At this level the mi-
tral valve area can be estimated by measuring 
the valve orifice with a planimeter during dias-
tole. Figures 6 and 7 show anatomic sections 
and a still frame of a tomographic section of the 
sector scan at the level of the aortic valve. 
RIGHT VENTRICLE 
POSTEROMEDIAL PAPILLARY 
MUSCLE 
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CUSP 
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"t..EFT VENTRICULAR 
OUTFLOW TRACT 
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LEAFLET 
LEFT ATRIUM 
POSTERtOR MlTRAL 
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Fig 1-Anatomic section of heart obtained in presumed plane of long axis of left ventricle. 
Fig 2-Long axis view of left ventricle with 2-D echo in a 
normal subject. Head of subject towards right, feet towards 
left, chest wall at the top, and spine at bottom of figure. An-
terior · (AL) and posterior (PL) leaflets of mitral valve and 
posteromedial papillary muscle (PM) are seen. RV = right 
ventricle, LV = left ventricle, VS = ventricular septum, PW 
= posterior left ventricular wall, LA= left atrium, AV= aor-
tic valve. 
3 . Apical four-chamber view. This view is ob-
tained by positioning the transducer over the 
point of maximal cardiac impulse with the pa-
tient in the left lateral position . The ventricles are 
at the top and the atria at the bottom. Figures 8 
and 9 are the diagrammatic and 2-D echo sec-
tions of this view. 
4. Suprasternal view. The transducer is in the 
suprasternal notch and the ultrasonic beam im-
SEPTUM Posq:~tHAl PAPlt.lAAY 
t.14$C1.E 
Fig 3-Anatomical section of heart along plane of ultra-
sonic tomographic section at level of papillary muscles. 
SAGAR: ECHOCARDIOGRAPHY / 59 
Fig 4-Ultrasonic tomographic section of left ventricle at 
the level of papillary muscles (PM). Papillary muscles are 
seen at approximately 3 and 8 o'clock positions. RV= right 
ventricle, LV = left ventricle, VS = ventricular septum, PW 
= posterior left ventricular wall, LA = left atrium, AV = aor-
tic valve. 
MON CORONARY 
Fig 5-Still frame of sector scan of short axis tomographic 
section of left ventricle at the level of mitral valve. In this fig-
ure, right ventricle is anterior and to the left. Left ventricle 
appears circular and is to the right. Anterior and posterior 
mitral leaflets have a fish mouth appearance during dias-
tole . RV = right ventricle, L V = left ventricle, VS = ven-
tricular septum, PW = posterior left ventricular wall, LA = 
left atrium, AV= aortic valve. 
Sf NUS 
Fig 6-Anatomic section of heart obtained along presumed ultrasonic tomographic section at level of aortic valve. 
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Fig 7---Still frame of a tomographic section at level of aortic 
valve. Aorta appears circular. Three leaflets of aortic valve 
during diastole form a Y (R = right, L = left, N = non-
coronary). Left atrial cavity is directly posterior to aortic root 
and left atrial appendage (LAA) is towards right of figure. 
Right atrium (RA) and tricuspid valve (TV) are on left of fig-
ure. Right ventricular outflow (RVO) tract, pulmonic valve 
(PV), and main pulmonary artery (MPA) are on top of figure. 
Atrial septum (AS) is also seen. 
ages the ascending aorta. This view is useful for 
the diagnosis of coarctation of the aorta. 5 
Contrast Echocardiography 
Contrast echocardiography is of value in 
detecting right-to-left shunt and tricuspid regur-
gitation. The usual contrast medium is a mixture 
of 5 ml of normal saline and 2 ml of air which 
are shaken together in a syringe to form micro-
cavities then injected into a peripheral vein . An 
important precaution is to avoid injecting visible 
air bubbles. Two ml of green dye produce simi-
lar results. Figure 1 0 shows opacification of the 
right atrium, right ventricle, and pulmonary ar-
tery, following an injection of normal saline in a 
tomographic section at the level of the aortic 
valve. 
Clinical Application of 2-D 
Echocardiography 
The 2-D echo is still in the developmental 
phase and further investigations are required to 
establish its accuracy, sensitivity, and specific-
ity. However, it has already made a significant 
contribution in the assessment of the severity of 
Fig 8-Left. Demonstration of placement of the transducer over apex and plane of tomogram. The image is displayed as if one 
were looking from below in the position of left hip, showing right and left atria (RA and LA) and right and left ventricles (RV and 
LV). Right. Section of the normal heart shown as it appears on the picture at left cardiac apex at top. RA = right atrium, LA 
= left atrium, RV= right ventricle, LV = left ventricle. 
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Fig 9---Diagrammatic representation (left) of apical image (right) . The right ventricle (RV) shows coarse trabeculation whereas 
the left ventricle (LV) is smooth. The tricuspid and mitral valves (TV and MV) are seen. The ventricular septum is seen between 
the two ventricles. The interatrial septum is seen between right and left atria (RA and LA). 
mitral and aortic stenosis, regional and global 
abnormalities of the left ventricular wall motion, 
and congenital heart diseases. 
Mitral Stenosis 
Quantitative assessment of the mitral 
valve area with 2-0 echo shows excellent corre-
lation with the mitral valve area obtained by car-
diac catheterization (r = 0 .95}6 and at opera-
tion (r = 0.92). 7 
Fig 10- Tomographic section at the level of aorta, after in-
travenous injection of normal saline. Note opacification of 
right atrium (RA) and right ventricular outflow (RVO) tract. 
Pulmonic valve (PV), aorta (AO), and left atrium (LA) are also 
seen. 
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Mitral Valve Prolapse and Flail Mitral Valve 
Two-dimensional echocardiography has 
accurately defined patterns of mitral valve pro-
lapse and flail mitral valve due to ruptured 
chordae tendinae. 8 
Aortic Stenosis 
Two-dimensional echocardiography not 
only localizes the level of aortic obstruction, that 
is, valvular, subvalvular or supravalvular9 but 
also allows noninvasive separation of significant 
from insignificant aortic stenosis. In our labora-
tory, patients with an aortic valve dia'meter of 
<1 .3 cm (obtained in the long axis) and con-
centric left ventricular hypertrophy had a mean 
aortic gradient of >50 mm Hg at cardiac cathe-
terization . 1 0 
Left Ventricular Wall Motion 
Regional and global left ventricular wall 
motion abnormalities can be studied non-
invasively. The 2-D echo provides an ultrasonic 
angiogram of the left ventricle and thus left ven-
tricular volumes and ejection fraction can be es-
timated. At the present time we still need valida-
tion of the accuracies and inaccuracies of the 
technique. 
Coronary Artery Disease 
There are reports of detection of left main 
coronary artery lesions with 2-D echo-
cardiography .11 Further investigations are 
needed to define sensitivity and specificity of 
this technique. 
Congenital Heart Disease 
Two-dimensional echocardiography 
should prove helpful in delineating cardiac anat-
omy in critically ill infants who are at a high risk 
tor cardiac catherization as well as aid in the di-
agnosis of lesions such as atrial septal defects, 
ventricular septal defects, A-V canal defects, 
and transposition of great vessels. 
In conclusion, the development of 2-D 
wide-angle echocardiography is a hallmark in 
the use of ultrasound as a diagnostic tool. It al-
lows simultaneous visualization of cardiac struc-
tures in real time through multiple planes with-
out known risk to the patient. 
Figures 1 , 2, 3 ,4, 5, 6, 7, and 1 0 are reproduced by 
permission from Mayo Clinic Proceedings (53:271-303, 
1978). 
Figures 8 and 9 are reproduced from Circulation 
(57:503-511, 1978) by permission of the American Heart 
Association, Inc. 
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Management of the Difficult Hypertensive 
Patient 
A. JARRELL RAPER, M.D. 
Associate Professor of Medicine, and Director, Outpatient Cardiology Services, Medical College of 
Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
Hypertension, while usually easily han-
dled , can in certain patients present difficult 
problems in management. 
Previous Neurological Disease 
A history of stroke sometimes creates 
doubt as to the advisability of lowering the blood 
pressure as this might reduce flow to the brain , 
causing the patient to have another stroke. It is 
recognized that severe hypertensives clearly do 
better if they are treated,' ·2 but the mild-to-mod-
era te hypertensive patient with a history of 
stroke is a more difficult problem , and uncer-
tainty about proper management has been so 
great that a large multicenter clinical trial-ran-
dom i zed, double-blind , and placebo-con-
trolled-of 452 patients was done by the 
Stroke-Hypertensive Study group, and its results 
reported in 1974. 3 All 452 patients had a his-
tory of a previous stroke and all had mild-to-
moderate diastolic hypertension . This study 
showed that long-term outpatient treatment of 
the blood pressure neither caused nor pre-
vented a second stroke. Other benefits such as 
a reduction in the number of episodes of con-
gestive heart failure were evident in the treated 
group. It would seem, then, that patients with a 
history of stroke should be treated for their dia-
stolic hypertension, unless there are other con-
traindications. 
Correspondence and reprint requests to Dr. A. Jarrell 
Raper , Box 1 05, Medical College of Virginia, Richmond , VA 
23298. 
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Isolated Systolic Hypertension 
Another difficult problem is that of "iso-
lated systolic hypertension ," that is , blood pres-
sure of 1 80 / 7 4 mm Hg , a condition common 
among older people. 
Data from the Framingham study have 
shown that the age-corrected morbidity ratio is 
correlated with systolic or diastolic hypertension 
or both ,4 as it is for stroke, congestive heart fail-
ure, and renal disease. Increased systolic blood 
pressure is therefore clearly a risk factor for car-
diovascular damage, and one might assume 
that it ought to be lowered. Of the large, care-
fully conducted blood pressure treatment trials 
that show patient benefit (decreased death or 
morbidity) , all required that patients have dias-
tolic hypertension to get into the study and did 
not include those with such pressures as 1 80 I 
7 4 mm Hg; these might have a stiff aorta and 
great vessels, requiring a high systolic pressure 
to pump a given stroke volume into the vascular 
system. In addition, treatment of the patient's 
180 mm Hg systolic pressure will also lower the 
diastolic pressure, which may be undesirable. 
Symptomless coronary heart disease does ex-
ist, and blood flow through the coronary arteries 
is, of course, heavily dependent upon diastolic 
pressure, even more so in the presence of dis-
eased arteries. 
When encountering a patient with a wide 
pulse pressure or with a severe systolic hyper-
tension and normal diastolic pressure , one 
should look for aortic insufficiency. Severe 
anemia, arteriovenous fistula, or thyrotox!cosis 
can also produce systolic hypertension. 
Once these conditions are ruled out, the 
decision to treat or not to treat must be faced. 
Unfortunately, there are no data to indicate that 
such patients can be helped by treating their 
isolated systolic hypertension. In the face of this 
uncertainty, treatment is recommended only 
when the patient has clear evidence of definite 
cardiovascular damage that appears to be due 
to the hypertension per se; definite left ventricu-
lar hypertrophy might be present, for example, 
with no other explanation. 
The systolic blood pressure usually rises 
with age in the American population 5 which puts 
some millions of primarily elderly people at risk 
for untreated hypertension or at risk for treat-
ment-induced complications. This is an impor-
tant clinical problem that has not yet had the 
systematic and careful study which it deserves. 
i 
Mild Diastolic Hypertension 
.Whether or not to treat mild diastolic high 
blood pressure (96 mm Hg) may also cause un-
certainty, but the Veterans Administration Coop-
erative Study Group, interpreted by Doctor 
Freis, has helped to clarify this question. 6 If the 
diastc)lic blood pressure is high enough (over 
1 04 mm Hg), one should go ahead and treat on 
the basis of the blood pressure alone . At lower 
levels, the presence of "risk factors" for hyper-
tensi\le damage should be sought. These in-
clude the usual risk factors for atherosclerosis, 
such as hypercholesterolemia, diabetes, family 
history, obesity, among others, and age (youth), 
and race (black). If several risk factors for hyper-
tensive damage are present, or if cardiovascular 
damage itself is already evident, one should 
treat the patient with borderline hypertension. 
Lack of Response to Therapy 
Occasionally, a patient may not respond 
to the prescribed medication . One reason for 
this might be incorrect cuff size. In dealing with 
an obese patient, this can be an important fac-
tor, causing as much as 1 O mm Hg diastolic 
error, or more. Current recommendations of the 
American Heart Association are for a cuff (blad-
der) width "25% greater than the diameter of 
the arm"; thus, the standard cuff bladder, 1 2 x 
22 cm, is suitable for a 1 0 cm (4-inch) diameter 
arm. 
Other reasons why the patient may not be 
responding to treatment could involve technical 
factors. For instance, if the patient is engaged in 
conversation while the pressure is being taken , 
the diastolic blood pressure rises slightly. A cold 
room also raises the blood pressure, systolic 
and diastolic, as does recent cigarette smoking 
or an office "climate" that is rushed and hur-
ried . A number of referrals have turned out to be 
patients who are able to recall that the office at-
mosphere in which their blood pressure was 
previously taken was hectic, or that they them-
selves were very rushed and hurried. 
Another reason for non-response is that 
the patient may not be taking his or her medica-
tion. An estimated 25% to 50% of patients (de-
pending upon definitions used) will be "non-
compliant.' ' Sometimes these individuals return 
regularly to see their doctor, even though they 
are not taking their medication; they may even 
count out the appropriate number of pills and 
throw them in the trash, so that the number re-
maining in the bottle appears to be correct to 
the physician. The best weapon against this is a 
good doctor-patient relationship in which the 
patient is assured of the physician's interest. 
For example , it helps to ask the patient if he or 
she is taking the prescribed medication regu-
larly. If the answer is yes and the patient seems 
to be certain about it, the physician should in-
quire if the medication was taken on schedule 
that day and the night before. If the patient ap-
pears at all uncertain, the physician can then 
describe the difficulty created by not following 
treatment , and how this can inadvertently cause 
over-treatment. Patient education as to the na-
ture of the disease and how complications are 
avoided has been carefully studied as a means 
to help compliance, but it has not been as suc-
cessful as had been hoped. 
Simplicity of treatment is very important . 
Most antihypertensive medications need only be 
taken twice a day at most. Drug combinations 
may help if the right combination can be found 
to fit the patient's needs. 
A patient may be complying with pre-
scribed medication and yet still not respond to 
treatment . The most common cause for this is 
subtle fluid retention . The body can retain any-
where from 5 to 11 pounds (depending on body 
size) of extra fluid without producing obvious 
edema that can be detected on physical exami-
nation; thus, a severe hypertensive should be 
weighed on every office visit. The extra fluid can 
be eliminated by salt restriction or by more pow-
erful diuretics; this will often restore the respon-
siveness of the patient to the same program of 
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antihypertensive medication . Frank congestive 
heart failure also interferes with the response to 
medications, as does deteriorating renal func-
tion, when blood pressure medicines can be-
come ineffective. 
Malignant (Accelerated) Phase of Hyper-
tension 
Non-response to treatment may be 
caused by the fact that the patient is entering 
the malignant phase of hypertension; high dias-
tolic pressures (130 mm Hg) will be present. 
This is, of course, a body-wide problem; the 
basic lesion, fibrinoid necrosis, occurs in arteri-
oles all over the body. The condition can be 
diagnosed in the office by the following clinical 
manifestations: 
1 . Acute hypertensive retinitis or reti-
nopathy: flame-shaped hemorrhages, 
and fluffy exudates, perhaps with pap-
illedema. 
2 . Hypertensive encephalopathy: diffuse 
cerebral dysfunction, perhaps with 
somnolence , coma, and/or con-
vulsions. 
3 . Malignant nephrosclerosis: microscopic 
or gross hematuria and proteinuria 
These manifestations are totally curable 
by lowering the blood pressure to normal, un-
less the renal lesion has progressed far enough 
to produce gross decrease in renal function, at 
which point renal damage may be arrested or 
slowed , but not cured. 
Once malignant hypertension has been 
halted , the prognosis is still poor. However, as 
long as the blood pressure is kept down , this 
syndrome will not return. Patients with newly-
discovered malignant hypertension should be 
hospitalized for immediate control of the blood 
pressure. 
Secondary Hypertension 
Trouble may occur with pressure control 
when the patient has an unrecognized cause of 
high blood pressure. Pheochromocytoma is a 
classic example and these patients have notori-
ously erratic blood pressure that is very difficult 
to control . Coarctation of the aorta can cause 
real trouble as very satisfactory blood pressure 
levels may be produced below the coarctation 
and yet be uncontrollable above the coarcta-
tion. Perhaps the patient is on birth-control hor-
mones which in some cases can cause pro-
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nounced hypertension. The possible use of 
artificial female hormones should be ascer-
tained in women of childbearing age or even 
post-childbearing years. 
Severe Hypertension 
Severe hypertension can be difficult to 
manage. Hemodynamic studies have shown 
that these patients have normal cardiac output, 
normal heart rate, normal stroke volume, and 
normal cerebral blood flow unless they are in 
heart failure or severe renal failure. Subtle alter-
ations in blood flow to several other parts of the 
body occur and renal blood flow is usually re-
duced. The small arterioles, because of their 
size, offer extremely high resistance to blood 
flow throughout the body. Treatment should be-
gin with a diuretic, not because there will be an 
adequate response to the diuretic alone but be-
cause it decreases the amount of other medica-
tions that are required, and is therefore a rea-
sonable foundation for therapy. 
Hydrochlorothiazide is usually used, 50 
mg twice a day, unless fluid retention is a prob-
lem, in which case furosemide is used; a low-
salt diet can help, as can weight loss if the pa-
tient is grossly obese. It is extremely difficult to 
get a grossly obese patient to lose weight, but 
when successful, the weight loss will lower the 
blood pressure to a surprising degree. 
Of course, other medications are going to 
be needed in addition to the thiazide. Methyl-
dopa or propranolol could be added . Methyl-
dopa is marketed as Aldomet. The highest dose 
that does any good in a large patient is a total of 
about 3. 5 gm a day divided into two doses. 
Beyond that, little, if any , blood pressure 
change occurs and there is the possibility of an 
increase in toxicity. 
Propranolol is marketed as lnderal and is 
a beta-receptor blocker. It affects not just the 
cardiovascular system but also blocks beta-re-
ceptors in the lungs and receptors in the endo-
crine system, so that there is the possibility of 
worsening of the asthmatic patient, or leaving 
the labile diabetic patient defenseless against 
hypoglycemia. It has recently been found that 
larger doses of propranolol are useful, and Eu-
ropean and Australian physicians are using up 
to 1 gm per day if the patient needs it and can 
tolerate it well . 7 We have not given quite this 
much at the Medical College of Virginia , but we 
are gradually moving to higher doses. Exactly 
why propranolol has a good effect on the blood 
pressure in these high-dosage ranges (beyond 
what seems to do any good for angina pectoris) 
is something of a mystery. Propranolol is better 
tolerated in some ways than guanethidine, and 
causes less orthostatic hypotension. 
Guanethidine is a useful and powerful 
antihypertensive but causes orthostatic hypo-
tension, as well as intestinal and sexual prob-
lems. The dose is extremely variable, and must 
be individually adjusted, but nearly all hyperten-
sive patients respond favorably to this drug. The 
problem is that it can produce intolerable side 
effects. Guanethidine and phenoxybenzamine 
given together have been shown to be useful in 
a few patients who do not respond to guanethi-
dine and a diuretic alone. 
A new beta-blocker has been recently 
marketed-metoprolol (Lopressor) . It is pro-
moted as being less toxic to the pulmonary and 
endocrine systems. There is evidence that it is 
especially useful in patients with obstructive 
lung disease, although it is not completely de-
void of action on pulmonary beta receptors. 
If a patient is unresponsive to thiazide plus 
propranolol or guanethidine, a vasodilator may 
be added. Hydralazine is an excellent vasodila-
tor and would be even more powerful if we 
could give enough. Long-term treatment must 
be limited to about 200 mg a day for an aver-
age-size patient because of a lupus-like syn-
drome that occurs at higher doses with disturb-
ing frequency. I do not know of a single 
convincing case of lupus-like syndrome at MCV 
caused by less than 200 mg of hydralazine, 
and I have been looking specifically for it for the 
last twelve years. 
Prazosin (Minipres) has been recently 
marketed as a vasodilator. There is some evi-
dence that it has an additional alpha-blockade 
effect, but the exact balance between these two 
actions is not well known . It is useful up to 20 
mg a day. 
If all these drugs have been tried and the 
hypertension is still uncontrolled, hospitalization 
is indicated. At this time the physician can de-
termine if any further action is required , such as 
an arteriogram, to eliminate the possibility of 
renal artery stenosis if the patient seems to be 
otherwise a reasonable surgical candidate for 
its correction . Hospitalization also presents an 
opportunity to look for other causes of hyper-
tension that might be corrected. Under these 
conditions, it is always possible to control the 
blood pressure somehow, using parenteral 
medications. Later, the patient can be taken off 
parenteral medication and put on oral agents. 
The patient will usually be more responsive to 
the drugs, at least for a while, after hospital-
ization. 
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SCRIPTA MEDICA 
Hyperuricemic Nephropathy: A 
Complication of Acute Leukemia in Children 
JAMES C. M. CHAN, M.D. 
Professor and Director, Nephrology Section, Department of Pediatrics, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
Introduction 
In order to provide a point of reference for 
a rational approach to the therapy of acute uric-
emic nephropathy, the metabolic pathways 
leading to the production of uric acid will be 
I 
briefly reviewed . 
Uric acid is the end-product of adenine 
and guanine metabolism. Relevant to this dis-
cussion is the xanthine oxidase enzyme which 
catalyzes the conversion of hypoxanthine to 
xanthine and xanthine to uric acid. In children 
with acute leukemia the increasing production 
and subsequent destruction of white blood cells 
result in the rapid elevation of uric acid concen-
tration in the plasma, especially during treat-
ment with antineoplastic drugs. This in turn may 
lead to the development of acute hyperuricemic 
nephropathy. 1 - 4 
The uric acid deposition in the renal me-
dulla causes obstructive uropathies. This occur-
rence is not uncommon in children treated for 
reticuloendothelial malignancies, sarcoma and 
acute lymphocytic leukemia. 
Incidence 
The work done at the National Cancer In-
stitute of the National Institutes of Health (NIH) 
Correspondence and reprint requests to Dr. James 
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mond, VA 23298. 
68 / MCV OUARTERL Y 15(2):68- 70, 1979 
showed that 6 out of 5 7 patients with acute leu-
kemia developed uric acid nephropathy.4 The 
treatment had consisted of methotrexate, 6-
mercaptopurine, hydrocortisone and cortisone. 
The duration of treatment before the clinical on-
set of hyperuricemic nephropathy was from 
three to six days. The maximum elevation of 
white cells was 11,800 to 18,000 per mm3 ; of 
uric acid from 1 7 to 71 ; and of BUN from 51 to 
212 mg/1 OOml. 
A number of subsequent reports have am-
ply confirmed and extended these observations 
of Frei et al, 4 and a number of conclusions can 
be made. 
Risk Factors 
Uric acid nephropathy is more prone to 
develop in the treatment of acute lymphocytic 
leukemia when the following conditions are 
present: elevation of white blood cells to more 
than 20,000/ mm3 , marked adenopathy, espe-
cially in the mediastinum, and massive hepa-
tosplenomegaly. 
The histology of severe uric acid nephrop-
athy includes intratubular hydronephrosis and 
infarction from uric acid obstruction5 ·6 ; the 
milder and more common form of uric acid ne-
phropathy shows marked renal enlargement 
produced by the intense interstitial leukemic in-
filtration; the glomeruli and tubules are intact. 
There is a good correlation between the kidney 
and liver size in patients with less than 5% leu-
kemic infiltration of these organs. 4 
Treatment 
The first two modes of treatment rely on 
the provisions of a more favorable situation for 
the deposition of uric acid which is reduced 
when the urinary pH is made alkaline in excess 
of 6, beyond which point the solubility of uric 
acid is increased in an exponential fashion . 
To insure a good urine output , intravenous 
5% dextrose/water is administered at a rate of 
3000 ml/m 2 /day. To promote uric acid solubil-
ity and therefore enhance excretion, the urine 
may be made alkaline by administering intra-
venous sodium bicarbonate at a dosage calcu-
lated to elevate the serum bicarbonate by 1 0 
mEq/liter, and/or the use of a carbonic anhy-
drase inhibitor acetazolamide to block the renal 
tubular reabsorption of bicarbonate. The aims 
of these general measures are to achieve a uri-
nary pH in excess of 6 and a urine volume in ex-
cess of 60 ml/m 2 /hour. 
If the urine output is less than 60 ml/m 2 / 
hour after rehydration, mannitol (25% aqueous 
solution) is given initially over a 5- to 1 0-minute 
period in a test dose of 6 .25 gm in children 
weighing less than 30 kg and 12.5 gm in chil-
dren weighing over 30 kg . If diuresis ensues, 
additional mannitol is administered in the same 
dose every 6 hours to achieve a urine output of 
at least 60 ml/m 2 /hour. 
It is important to obtain and record urine 
volume, pH, body weight, vital signs, blood uric 
acid, electrolytes, BUN, and calcium concentra-
tions every 1 2 to 24 hours. 
Normal glomerular filtration rates are 
achieved within 2 to 1 4 days of treatment of hy-
peruricemia with fluids , bicarbonate and aceta-
zolamide. 7 
Allopurinol 
Allopurinol (1 0 mg/kg/day initial oral 
dose) is a useful drug for the treatment of hyper-
uricemia. 7 ·8 Allopurinol is a potent inhibitor of 
xanthine oxidase for which it is also a substrate. 
Although the incidence of side effects is 
very low, the potential complications of allopuri-
nol treatment should always be kept in mind . 
These include skin and blood dyscrasias, ma-
laise, fever, complaints of nausea, headache, 
vomiting, vertigo, drowsiness and gastric irrita-
tion, muscle ache, elevation of SGOT /SGPT, 
leLJcocytosis, leucopenia and, rarely, peripheral 
neuritis and bone marrow depression . 
Special Therapy 
The rapid removal of uric acid can be 
achieved by either peritoneal dialysis or hemo-
dialysis. 
Peritoneal dialysis removes uric acid at a 
rate of 1 5 ml / min, but hemodialysis is at least 
five times more effective.1·2 The decision on 
when to institute these procedures is a clinical 
one and is based on the physician 's past expe-
rience and the patient's status . One example of 
this complex clinical decision is shown in the 
Figure . 
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Figure--Acute uric acid nephropathy and treatment with 
hemodialysis is illustrated in the clinical course of a 1 4-year-
old white boy. 
Acute uric acid nephropathy occurred at the time 
of leukemic relapse. Diuresis did not occur despite 
all the general treatment procedures. Peritoneal 
dialysis was only partially successful in the re-
moval of 4 gm of uric acid in 24 hours without 
lowering the serum uric acid concentration. Hemo 
dialysis was instituted and removed over 1 7 gm of 
uric acid resulting in a decrease of serum uric acid 
from 87 to 29 mg/di. Immediately following dial-
ysis, he was given 25 gm of intravenous mannitol 
and was started on allopurinol. However, anuria 
persisted and a second course of hemodialysis 
was performed for 6 hours, resulting in a decrease 
of serum uric acid from 46 to 19 mg/di. Just be-
fore the completion of the dialysis, he voided 340 
ml of urine and the output remained adequate 
thereafter aided by good fluid and conservative 
medical management. 
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The use of hemodialysis is dependent on 
machine availability and the existence of a spe-
cially trained nephrology team consisting of 
dialysis technicians, nurses, surgeons, and 
nephrologists. Peritoneal dialysis requires less 
technical hardware and can be initiated more 
promptly by the nephrologist; whereas, before 
hemodialysis can be initiated, vascular access 
and somewhat extensive preparations are 
needed, especially in small children in the 2- to 
3-year age group, where uric acid nephropathy 
more commonly occurs. 
There is a relationship between the days 
of oliguria before dialysis has been started and 
the number of days until diuresis begins2 which 
has been taken as an indication for the early in-
stitution of either of these special procedures 
within a day or two of anuria and/or rapidly ris-
ing serum uric acid concentrations. 
Summary 
Hyperuricemic acute nephropathy occurs 
in 1 0% of patients with leukemia; the intrarenal 
uric acid deposition results in obstructive uro-
pathy. 
The clinical findings which point to the 
likelihood of renal damage are: first, an initial 
white blood cell count in excess of 20,000/ 
mm3 ; second, marked adenopathy especially in 
the mediastinum; and third, the presence of 
massive hepatosplenomegaly. The aim of gen-
eral treatment with fluids and renal alkalinization 
is to promote uric acid solubility and output by 
maintaining urine pH in excess of 6 and urine 
volume in excess of 60 ml / m2 / hr. The discov-
ery and clinical use of allopurinol, an analogue 
of hypoxanthine and an inhibitor as well as a 
substrate of the enzyme xanthine oxidase, is 
central to the control of hyperuricemia. Allopuri-
nol , as well as its metabolic end-product, allo-
xanthine, acts at the terminal steps of uric acid 
metabolism to reduce the production of uric 
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acid and in conjunction with the other general 
medical therapy, contributes to the reversal of 
the hyperuricemia. 
Finally, the special extrarenal procedures 
of peritoneal dialysis and hemodialysis can rap-
idly, efficiently and safely remove the uric acid 
from the body. The sooner one initiates either of 
these procedures, the earlier diuresis begins. 
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